Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00693225 · ClinicalTrials.gov registry record · Phase 4
Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study
A Phase 4 study of Erosive Esophagitis, sponsored by Yvonne Romero.
- Completed
- Registry status
- Phase 4
- Development phase
- 91
- Enrollment target
- 1
- Study location
NCT00693225 is a Phase 4 study of Erosive Esophagitis that has completed, run by Yvonne Romero. The registered enrollment target is 91 participants, below the 196-participant average among 6 other Erosive Esophagitis trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00693225, a Phase 4 study of Erosive Esophagitis, has completed, sponsored by Yvonne Romero.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 91 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study was to determine the effect of morning versus bedtime administration of omeprazole/sodium bicarbonate (Zegerid) on endoscopic healing for patients with moderate or severe reflux esophagitis. Our hypothesis was that bedtime administration of Zegerid would be superior in healing esophagitis compared to morning administration prior to a meal.
Conditions Studied
Interventions
- DRUG Omeprazole/sodium bicarbonate
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00693225
The ClinicalTrials.gov registry entry for NCT00693225 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 196-participant average among 6 other Erosive Esophagitis trials with a reported enrollment target (54% lower). The listed sponsor is Yvonne Romero, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Erosive Esophagitis appearing as the primary indexed condition, and to 1 intervention - of which Omeprazole/sodium bicarbonate is the first listed.
NCT00693225 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00693225 about?
NCT00693225 is a clinical study titled "Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study". The purpose of this study was to determine the effect of morning versus bedtime administration of omeprazole/sodium bicarbonate (Zegerid) on endoscopic healing for patients with moderate or severe reflux esophagitis. Our hypothesis was that bedtime administration of Zegerid would be superior in heal...
What is the current status of trial NCT00693225?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 91 participants. The study started on 2008-01. Estimated completion is 2010-12.
What conditions does trial NCT00693225 study?
This clinical trial studies the following conditions: Erosive Esophagitis.
What interventions are being tested in trial NCT00693225?
The interventions under investigation include: Omeprazole/sodium bicarbonate (DRUG).
Who is sponsoring clinical trial NCT00693225?
This trial is sponsored by Yvonne Romero, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00693225 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Erosive Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
RECRUITING · Phase 3
-
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
RECRUITING · Phase 2
-
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
RECRUITING
-
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
COMPLETED · Phase 2
-
A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole
COMPLETED · Phase 2
-
Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.